Roche

News

Kadcyla finally gets OK after price cut and NICE concessions

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.

News

Chicago, IL - 2017 ASCO Annual Meeting - Attendees and poster presenters during Posters Sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Saturday June 3, 2017. Over 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 53rd Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/David Eulitt 2017 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org

High cost of cancer drugs takes centre stage at ASCO

The cost of cancer drugs became a major talking point at this year’s ASCO conference, where doctors raised concerns about the “financial toxicity” patients face in paying for very expensive

News

Puma gains as Roche breast cancer combo disappoints

ASCO serves up shock as Roche's data disappoints

News

Brain infection would be bad news for Roche's MS drug Ocrevu...

Suggestion is that PML case was caused by previous treatment.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA advisers back Puma breast cancer drug despite safety wor...

But biotech still has several hurdles to clear - including Roche's rival.

News

Celltrion's rituximab biosimilar could have four names in EU

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands.

Kadcyla finally gets OK after price cut and NICE concessions

High cost of cancer drugs takes centre stage at ASCO

Puma gains as Roche breast cancer combo disappoints

Brain infection would be bad news for Roche's MS drug Ocrevu...

FDA advisers back Puma breast cancer drug despite safety wor...

Celltrion's rituximab biosimilar could have four names in EU

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

Roche

Editor's Picks